卡博替尼再挑战治疗转移性肾细胞癌的疗效与安全性:一项回顾性多中心研究
这项回顾性多中心研究评估了卡博替尼再挑战(首次暴露后间隔≥3个月未治疗或≥1种其他治疗线后再次暴露)在转移性肾细胞癌患者中的疗效与安全性。2017至2022年间共纳入51例患者,再挑战时中位无进展生存期为14.4个月,客观缓解率为60%,未出现非预期不良事件。作者认为卡博替尼再挑战是可行的治疗选择,可能具有临床获益。
要点
- 再挑战时中位无进展生存期为14.4个月(95%CI 9.8-NR)。
- 再挑战时客观缓解率为60%,首次暴露时为70.6%。
- 首次暴露无进展生存期>12个月及因毒性停用首次暴露者,再挑战无进展生存期更高但未达统计学显著。
核心结论
- 作者认为,卡博替尼再挑战是转移性肾细胞癌患者一种可行的治疗选择,可能具有临床获益。
研究设计与样本
- 回顾性多中心研究,评估卡博替尼再挑战在转移性肾细胞癌患者中的疗效与安全性。
- 再挑战定义为首次暴露后间隔≥3个月未治疗或≥1种其他治疗线后再次暴露。
- 共纳入51例在2017年至2022年间接受卡博替尼再挑战的转移性肾细胞癌患者。
- 主要终点为再挑战时的中位无进展生存期,次要终点包括总生存期、客观缓解率和再挑战时的安全性。
主要发现
- 诊断时中位年龄为54岁,78%为男性,90%为透明细胞型转移性肾细胞癌,92%既往接受过肾切除术。
- 15例患者(29%)在治疗暂停后再挑战,36例(70.6%)在首次卡博替尼暴露(CABO-1)与再挑战(CABO-2)之间接受过≥1种其他治疗线。
- CABO-1的中位无进展生存期为15.1个月(95%CI 11.2-22.1),CABO-2为14.4个月(95%CI 9.8-NR)。
- CABO-1的中位总生存期为67.6个月(95%CI 52.2-NR),CABO-2为27.4个月(95%CI 17.2-NR);客观缓解率CABO-1为70.6%,CABO-2为60%。
- CABO-1无进展生存期>12个月的患者及因毒性停用CABO-1的患者,CABO-2的无进展生存期更高,但未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite metastatic renal cell carcinoma (mRCC) expanded treatment options, disease progression ultimately occurs for most patients. Rechallenge may be a compelling strategy in a refractory setting. Cabozantinib is the standard of care in first and later lines of therapy, but its activity in rechallenge is unknown. METHODS: This retrospective study assessed the efficacy and safety of cabozantinib rechallenge, as defined by a second exposure after an interval of ≥3 months without treatment or ≥1 other treatment line, in patients with mRCC. The primary endpoint was median progression-free survival (PFS) at rechallenge. Secondary endpoints included overall survival, objective response rate, and safety at rechallenge. RESULTS: We included 51 mRCC patients who received cabozantinib in a rechallenge setting between 2017 and 2022. Median age at diagnosis was 54 years, 78% were male, 90% had clear cell mRCC, and 92% had prior nephrectomy. 15 patients (29%) were rechallenged after a pause in treatment, whereas 36 (70.6%) had ≥1 other treatment lines between first cabozantinib exposure (CABO-1) and rechallenge (CABO-2). Median PFS was 15.1 months (mo, 95% Confidence interval 11.2-22.1) at CABO-1 and 14.4mo (95%CI 9.8-NR) at CABO-2. Median overall survival was 67.6mo for CABO-1 (95% CI 52.2-NR) and 27.4mo for CABO-2 (95%CI 17.2-NR); objective response rate was 70.6% for CABO-1 and 60% for CABO-2. CABO-2 PFS was higher for patients with CABO-1 PFS > 12 months, and for those who discontinued CABO-1 because of toxicity, without statistical significance. There were no unexpected adverse events. CONCLUSIONS: Cabozantinib rechallenge is a feasible treatment option with potential clinical benefit for mRCC patients.
引用
- Baudry E, Naoun N, Auclin E, et al. Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study. Eur J Cancer. 2023. PMID: 37717282. doi:10.1016/j.ejca.2023.113292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。